New Delhi . The Modi government at the Center has given instructions to reduce the maximum retail price (MRP) of anti-cancer drugs like trastuzumab, osimertinib and durvalumab. The National Pharmaceutical Pricing Authority (NPPA) said in a statement that it has directed drug manufacturers to reduce the MRP on three anti-cancer drugs such as trastuzumab, osimertinib and durvalumab.
There should be reduction in MRP of medicines in the market
There should be a reduction in the MRP of medicines in the market due to exemption from customs duty and reduction in GST rates and the benefit of reduction in taxes and duties should be passed on to the common consumers. Therefore, NPPA has directed all the manufacturers of these medicines through office memorandum to reduce the MRP of these medicines. This directive is in line with the announcement made in the Union Budget for the year 2024-25, in which these three anti-cancer drugs have been exempted from customs duty. The Finance Ministry has reduced the customs duty on these three anti-cancer drugs to zero. Notification has been issued to reduce GST rates on these three medicines from 12 to five percent.